期刊文献+

Predictors of the patency of self-expandable metallic stents in malignant gastroduodenal obstruction

Predictors of the patency of self-expandable metallic stents in malignant gastroduodenal obstruction
下载PDF
导出
摘要 AIM:To investigate the predictive factors of selfexpandable metallic stent patency after stent placement in patients with inoperable malignant gastroduodenal obstruction. METHODS:A total of 116 patients underwent stent placements for inoperable malignant gastroduodenal obstruction at a tertiary academic center. Clinical success was defined as acceptable decompression of the obstructive lesion within the malignant gastroduodenal neoplasm. We evaluated patient comorbidities and clinical statuses using the World Health Organization's scoring system and categorized patient responses to chemotherapy using the Response Evaluation Criteria in Solid Tumors criteria. We analyzed the relationships between possible predictive factors and stent patency. RESULTS:Self-expandable metallic stent placement was technically successful in all patients(100%),and the clinical success rate was 84.2%. In a multivariate Cox proportional hazards model,carcinoembryonic antigen(CEA) levels were correlated with a reduction in stent patency [P = 0.006; adjusted hazard ratio(a HR)= 2.92,95%CI:1.36-6.25]. Palliative chemotherapy was statistically associated with an increase in stent patency(P = 0.009; a HR = 0.27,95%CI:0.10-0.72).CONCLUSION:CEA levels can easily be measured at the time of stent placement and may help clinicians to predict stent patency and determine the appropriate stent procedure. AIM:To investigate the predictive factors of selfexpandable metallic stent patency after stent placement in patients with inoperable malignant gastroduodenal obstruction. METHODS:A total of 116 patients underwent stent placements for inoperable malignant gastroduodenal obstruction at a tertiary academic center. Clinical success was defined as acceptable decompression of the obstructive lesion within the malignant gastroduodenal neoplasm. We evaluated patient comorbidities and clinical statuses using the World Health Organization's scoring system and categorized patient responses to chemotherapy using the Response Evaluation Criteria in Solid Tumors criteria. We analyzed the relationships between possible predictive factors and stent patency. RESULTS:Self-expandable metallic stent placement was technically successful in all patients(100%),and the clinical success rate was 84.2%. In a multivariate Cox proportional hazards model,carcinoembryonic antigen(CEA) levels were correlated with a reduction in stent patency [P = 0.006; adjusted hazard ratio(a HR)= 2.92,95%CI:1.36-6.25]. Palliative chemotherapy was statistically associated with an increase in stent patency(P = 0.009; a HR = 0.27,95%CI:0.10-0.72).CONCLUSION:CEA levels can easily be measured at the time of stent placement and may help clinicians to predict stent patency and determine the appropriate stent procedure.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第30期9134-9141,共8页 世界胃肠病学杂志(英文版)
基金 Supported by Technology Innovation Program(or Industrial Strategic technology development program),No.10049743,Establishing a medical device development open platform,as a hub for accelerating close firm-hospital communication)funded By the Ministry of Trade,industry and Energy(MI,South Korea)
关键词 MALIGNANT GASTRODUODENAL OBSTRUCTION STENT PATENCY Predictive factor Carcinoembryonicantigen Malignant gastroduodenal obstruction Stent Patency Predictive factor Carcinoembryonic antigen
  • 相关文献

参考文献34

  • 1Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK,Coleman J, Pitt HA, Yeo CJ. Is prophylactic gastrojejunostomyindicated for unresectable periampullary cancer- A prospectiverandomized trial. Ann Surg 1999; 230: 322-328; discussion 328-330[PMID: 10493479 DOI: 10.1097/00000658-199909000-00005].
  • 2Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, LevyP, Ruszniewski P. Long-term outcome of biliary and duodenal stentsin palliative treatment of patients with unresectable adenocarcinomaof the head of pancreas. Am J Gastroenterol 2006; 101: 735-742[PMID: 16635221 DOI: 10.1111/j.1572-0241.2006.00559.x].
  • 3van Hooft JE, Dijkgraaf MG, Timmer R, Siersema PD, FockensP. Independent predictors of survival in patients with incurablemalignant gastric outlet obstruction: a multicenter prospectiveobservational study. Scand J Gastroenterol 2010; 45: 1217-1222[PMID: 20459356 DOI: 10.3109/00365521.2010.487916].
  • 4Jeurnink SM, Steyerberg EW, Hof Gv, van Eijck CH, Kuipers EJ,Siersema PD. Gastrojejunostomy versus stent placement in patientswith malignant gastric outlet obstruction: a comparison in 95patients. J Surg Oncol 2007; 96: 389-396 [PMID: 17474082 DOI:10.1002/jso.20828].
  • 5Weaver DW, Wiencek RG, Bouwman DL, Walt AJ. Gastrojejunostomy:is it helpful for patients with pancreatic cancer-Surgery 1987; 102: 608-613 [PMID: 2443991].
  • 6Fujino Y, Suzuki Y, Kamigaki T, Mitsutsuji M, Kuroda Y.Evaluation of gastroenteric bypass for unresectable pancreatic cancer.Hepatogastroenterology 2001; 48: 563-568 [PMID: 11379354].
  • 7Del Piano M, Ballarè M, Montino F, Todesco A, Orsello M,Magnani C, Garello E. Endoscopy or surgery for malignant GIoutlet obstruction- Gastrointest Endosc 2005; 61: 421-426 [PMID:15758914].
  • 8van Hooft JE, van Montfoort ML, Jeurnink SM, Bruno MJ,Dijkgraaf MG, Siersema PD, Fockens P. Safety and efficacy of anew non-foreshortening nitinol stent in malignant gastric outletobstruction (DUONITI study): a prospective, multicenter study.Endoscopy 2011; 43: 671-675 [PMID: 21656455 DOI: 10.1055/s-0030-1256383].
  • 9Chandrasegaram MD, Eslick GD, Mansfield CO, Liem H,Richardson M, Ahmed S, Cox MR. Endoscopic stenting versusoperative gastrojejunostomy for malignant gastric outlet obstruction.Surg Endosc 2012; 26: 323-329 [PMID: 21898024 DOI: 10.1007/s00464-011-1870-3].
  • 10van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD,Dijkgraaf MG, Fockens P. Efficacy and safety of the new WallFlexenteral stent in palliative treatment of malignant gastric outletobstruction (DUOFLEX study): a prospective multicenter study.Gastrointest Endosc 2009; 69: 1059-1066 [PMID: 19152912 DOI:10.1016/j.gie.2008.07.026].

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部